再獲美國大單!九安醫療連續第二日上漲
格隆匯11月24日丨繼昨日收漲6.47%後,九安醫療今日繼續走強,盤中一度再漲超9%至62.34元,股價創7月14日以來新高。消息面上,11月23日早間,九安醫療發佈公吿稱,美國子公司和美國DLA(美國國防部後勤局)於當地時間11月22日簽訂了iHealth試劑盒產品的採購合同,合同價税合計金額為1.91億美元(含運費),約合人民幣13.67億元,超過公司2021年度經審計主營業務收入的50%。不過,九安醫療公吿同時指出,上述合同履行比例達到20%(即1440萬人iHealth試劑盒,對應合同金額3816萬美元)後,買方有權終止該合同。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.